{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:39:42Z","timestamp":1791175182089,"version":"4.1.0"},"reference-count":100,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,7,1]]},"abstract":"<jats:p>Coronary artery disease (CAD) is the leading cause of death worldwide. The efficacy and safety of statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) in primary and secondary prevention of CAD are confirmed in several large studies. It is well known that statins have some pleiotropic, anti-atherosclerotic effects. We review the molecular mechanisms underlying the beneficial effects of statins revealed in recently published studies. Endothelial cell injury is regarded as the classic stimulus for the development of atherosclerotic lesions. In addition, the inflammatory process plays an important role in the aetiology of atherosclerosis. In particular, chronic inflammation plays a key role in coronary artery plaque instability and subsequent occlusive thrombosis. Our previous reports and others have demonstrated beneficial effects of statins on endothelial dysfunction and chronic inflammation in CAD. A better understanding of the molecular mechanism underlying the effectiveness of statins against atherosclerosis may provide a novel therapeutic agent for the treatment of coronary atherosclerosis. The present review summarizes the cellular and molecular mechanism of statins against coronary atherosclerosis.<\/jats:p>","DOI":"10.1042\/cs20150027","type":"journal-article","created":{"date-parts":[[2015,4,24]],"date-time":"2015-04-24T14:57:45Z","timestamp":1429887465000},"page":"93-105","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["Cellular and molecular mechanisms of statins: an update on pleiotropic effects"],"prefix":"10.1042","volume":"129","author":[{"given":"Mamoru","family":"Satoh","sequence":"first","affiliation":[{"name":"Division of Biomedical Information Analysis, Institute for Biomedical Sciences, Iwate Medical University, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Tabuchi","sequence":"additional","affiliation":[{"name":"Division of Cardioangiology, Nephrology and Endocrinology, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Minami","sequence":"additional","affiliation":[{"name":"Division of Cardioangiology, Nephrology and Endocrinology, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Tamada","sequence":"additional","affiliation":[{"name":"Division of Cardioangiology, Nephrology and Endocrinology, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kan","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomonori","family":"Itoh","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Morino","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motoyuki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Division of Cardioangiology, Nephrology and Endocrinology, Iwate Medical University School of Medicine, Iwate, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2015,4,24]]},"reference":[{"key":"2021113010411368700_B1","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"2021113010411368700_B2","doi-asserted-by":"publisher","first-page":"3825","DOI":"10.1172\/JCI60457","article-title":"ApoE controls the interface linking lipids and inflammation in atherosclerosis","volume":"121","author":"Weber","year":"2011","journal-title":"J. Clin. Invest."},{"key":"2021113010411368700_B3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.atherosclerosis.2004.07.003","article-title":"Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients","volume":"177","author":"Ascer","year":"2004","journal-title":"Atherosclerosis"},{"key":"2021113010411368700_B4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/S0021-9150(02)00316-7","article-title":"Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type\u00a02 diabetes mellitus","volume":"166","author":"van de Ree","year":"2003","journal-title":"Atherosclerosis"},{"key":"2021113010411368700_B5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/S0021-9150(99)00189-6","article-title":"HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease","volume":"147","author":"J\u00e4rvisalo","year":"1999","journal-title":"Atherosclerosis"},{"key":"2021113010411368700_B6","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1161\/01.CIR.99.25.3227","article-title":"Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial","volume":"99","author":"Dupuis","year":"1999","journal-title":"Circulation"},{"key":"2021113010411368700_B7","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"2021113010411368700_B8","doi-asserted-by":"publisher","first-page":"3198","DOI":"10.1161\/STROKEAHA.107.493106","article-title":"Effects of intense low density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial","volume":"38","author":"Amarenco","year":"2007","journal-title":"Stroke"},{"key":"2021113010411368700_B9","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1161\/01.CIR.103.3.387","article-title":"Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project","volume":"103","author":"Byington","year":"2001","journal-title":"Circulation"},{"key":"2021113010411368700_B10","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/01.CIR.0000136588.62638.5E","article-title":"Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study","volume":"110","author":"Kinlay","year":"2004","journal-title":"Circulation"},{"key":"2021113010411368700_B11","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1016\/j.ahj.2008.04.020","article-title":"The effects of atorvastatin on the occurrence of postoperative atrial fibrillation after off-pump coronary artery bypass grafting surgery","volume":"156","author":"Song","year":"2008","journal-title":"Am. Heart J."},{"key":"2021113010411368700_B12","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1093\/eurheartj\/ehp357","article-title":"Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial","volume":"30","author":"Maggioni","year":"2009","journal-title":"Eur. Heart J."},{"key":"2021113010411368700_B13","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B14","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.metabol.2010.08.013","article-title":"Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor atorvastatin and hepatic LRP1 expression","volume":"60","author":"Moon","year":"2011","journal-title":"Metabolism"},{"key":"2021113010411368700_B15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0140-6736(06)69472-5","article-title":"Primary prevention of cardiovascular disease with pravastatin in Japan (MEGAStudy): a prospective randomised controlled trial","volume":"368","author":"Nakamura","year":"2006","journal-title":"Lancet"},{"key":"2021113010411368700_B16","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"2021113010411368700_B17","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B18","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B19","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease","volume":"344","author":"The Scandinavian Simvastatin Survival Study (4S)","year":"1994","journal-title":"Lancet"},{"key":"2021113010411368700_B20","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"2021113010411368700_B21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B22","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B23","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B24","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.jacc.2005.03.077","article-title":"Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT\u2013TIMI 22 trial","volume":"46","author":"Ray","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010411368700_B25","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1161\/ATVBAHA.107.151787","article-title":"Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study","volume":"28","author":"Kinlay","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010411368700_B26","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1161\/01.CIR.0000091404.09558.AF","article-title":"Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study","volume":"108","author":"Kinlay","year":"2003","journal-title":"Circulation"},{"key":"2021113010411368700_B27","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"2021113010411368700_B28","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/eurheartj\/ehi881","article-title":"Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for \u2018pleiotropic\u2019 functions of statin therapy","volume":"27","author":"Fichtlscherer","year":"2006","journal-title":"Eur. Heart J."},{"key":"2021113010411368700_B29","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"2021113010411368700_B30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1161\/01.CIR.0000140677.20606.0E","article-title":"Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults","volume":"110","author":"Malik","year":"2004","journal-title":"Circulation"},{"key":"2021113010411368700_B31","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/01.CIR.0000025404.78001.D8","article-title":"Prognostic value of coronary vascular endothelial dysfunction","volume":"106","author":"Halcox","year":"2002","journal-title":"Circulation"},{"key":"2021113010411368700_B32","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1161\/01.ATV.0000058402.34138.11","article-title":"Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study","volume":"23","author":"Keaney","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010411368700_B33","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0167-4889(99)00163-9","article-title":"Effects of hypoxia and glutathione depletion on hemoglobin- and myoglobin-mediated oxidative stress toward endothelium","volume":"1495","author":"D'Agnillo","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"2021113010411368700_B34","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1172\/JCI114562","article-title":"Minimally modified LDL stimulates monocyte endothelial interaction","volume":"85","author":"Berliner","year":"1990","journal-title":"J. Clin. Invest."},{"key":"2021113010411368700_B35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1161\/01.HYP.38.1.48","article-title":"Endothelial apoptosis induced by oxidative stress through activation of NF-kappaB: antiapoptotic effect of antioxidant agents on endothelial cells","volume":"38","author":"Aoki","year":"2001","journal-title":"Hypertension"},{"key":"2021113010411368700_B36","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1126\/science.275.5302.964","article-title":"Isolation of putative progenitor endothelial cells for angiogenesis","volume":"275","author":"Asahara","year":"1997","journal-title":"Science"},{"key":"2021113010411368700_B37","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1056\/NEJMoa043814","article-title":"Circulating endothelial progenitor cells and cardiovascular outcomes","volume":"353","author":"Werner","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B38","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood.V92.2.362","article-title":"Evidence for circulating bone marrow-derived endothelial cells","volume":"92","author":"Shi","year":"1998","journal-title":"Blood"},{"key":"2021113010411368700_B39","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1161\/01.CIR.0000018166.84319.55","article-title":"Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells","volume":"105","author":"Walter","year":"2002","journal-title":"Circulation"},{"key":"2021113010411368700_B40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/nm0603-702","article-title":"Therapeutic stem and progenitor cell transplantation for organ vascularization and regeneration","volume":"9","author":"Rafii","year":"2003","journal-title":"Nat. Med."},{"key":"2021113010411368700_B41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0092-8674(01)00492-5","article-title":"Switching and signaling at the telomere","volume":"106","author":"Blackburn","year":"2001","journal-title":"Cell"},{"key":"2021113010411368700_B42","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.atherosclerosis.2007.09.040","article-title":"Association between oxidative DNA damage and telomere shortening in circulating endothelial progenitor cells obtained from metabolic syndrome patients with coronary artery disease","volume":"198","author":"Satoh","year":"2008","journal-title":"Atherosclerosis"},{"key":"2021113010411368700_B43","doi-asserted-by":"publisher","first-page":"3136","DOI":"10.1161\/01.CIR.0000142866.50300.EB","article-title":"Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2\u00a0in endothelial progenitor cells","volume":"110","author":"Spyridopoulos","year":"2004","journal-title":"Circulation"},{"key":"2021113010411368700_B44","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"2021113010411368700_B45","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1042\/CS20080404","article-title":"Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease","volume":"116","author":"Satoh","year":"2009","journal-title":"Clin. Sci."},{"key":"2021113010411368700_B46","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev.immunol.21.120601.141126","article-title":"Toll-like receptors","volume":"21","author":"Takeda","year":"2003","journal-title":"Annu. Rev. Immunol."},{"key":"2021113010411368700_B47","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/35100529","article-title":"Toll-like receptors and innate immunity","volume":"1","author":"Medzhitov","year":"2001","journal-title":"Nat. Rev. Immunol."},{"key":"2021113010411368700_B48","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/90609","article-title":"Toll-like receptors: critical proteins linking innate and acquired immunity","volume":"2","author":"Akira","year":"2001","journal-title":"Nat. Immunol."},{"key":"2021113010411368700_B49","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/41131","article-title":"A human homologue of the Drosophila Toll protein signals activation of adaptive immunity","volume":"388","author":"Medzhitov","year":"1997","journal-title":"Nature"},{"key":"2021113010411368700_B50","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJM199906103402312","article-title":"The Toll of innate immunity on microbial pathogens","volume":"340","author":"Modlin","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B51","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ijcard.2005.06.023","article-title":"Activated toll-like receptor 4\u00a0in monocytes is associated with heart failure after acute myocardial infarction","volume":"109","author":"Satoh","year":"2006","journal-title":"Int. J. Cardiol."},{"key":"2021113010411368700_B52","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ejheart.2006.03.004","article-title":"Elevated circulating levels of heat shock protein 70 are related to systemic inflammatory reaction through monocyte Toll signal in patients with heart failure after acute myocardial infarction","volume":"8","author":"Satoh","year":"2006","journal-title":"Eur. J. Heart Fail."},{"key":"2021113010411368700_B53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1042\/CS20070379","article-title":"Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction","volume":"115","author":"Ishikawa","year":"2008","journal-title":"Clin. Sci."},{"key":"2021113010411368700_B54","doi-asserted-by":"publisher","first-page":"10679","DOI":"10.1073\/pnas.0403249101","article-title":"Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E","volume":"101","author":"Michelsen","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010411368700_B55","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa042000","article-title":"Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease","volume":"352","author":"Nissen","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"2021113010411368700_B57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1189\/jlb.0205064","article-title":"Differential effects of statins on relevant functions of human monocyte-derived dendritic cells","volume":"79","author":"Yilmaz","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"2021113010411368700_B58","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.atherosclerosis.2012.08.037","article-title":"Effect of simvastatin or its combination with ezetimibe on Toll-like receptor expression and lipopolysaccharide-induced cytokine production in monocytes of hypercholesterolemic patients","volume":"225","author":"Moutzouri","year":"2012","journal-title":"Atherosclerosis"},{"key":"2021113010411368700_B59","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/35025203","article-title":"Atherosclerosis","volume":"407","author":"Lusis","year":"2000","journal-title":"Nature"},{"key":"2021113010411368700_B60","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.cardiores.2004.12.027","article-title":"Endothelial aging","volume":"66","author":"Brandes","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"2021113010411368700_B61","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.amjsurg.2005.07.017","article-title":"Differential responsiveness of early- and late-passage endothelial cells to shear stress","volume":"190","author":"Kudo","year":"2005","journal-title":"Am. J. Surg."},{"key":"2021113010411368700_B62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1161\/01.RES.0000256837.40544.4a","article-title":"Vascular cell senescence: contribution to atherosclerosis","volume":"100","author":"Minamino","year":"2007","journal-title":"Circ. Res."},{"key":"2021113010411368700_B63","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1006\/bbrc.2000.3000","article-title":"Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins","volume":"273","author":"Frye","year":"2000","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021113010411368700_B64","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1101\/gad.7.4.592","article-title":"Transcriptional silencing in yeast is associated with reduced nucleosome acetylation","volume":"7","author":"Braunstein","year":"1993","journal-title":"Genes Dev."},{"key":"2021113010411368700_B65","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.4161\/cc.7.14.6267","article-title":"Emerging roles of SIRT1\u00a0in vascular endothelial homeostasis","volume":"7","author":"Potente","year":"2008","journal-title":"Cell Cycle"},{"key":"2021113010411368700_B66","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.yjmcc.2007.08.008","article-title":"Sirt1 modulates premature senescence-like phenotype in human endothelial cells","volume":"43","author":"Ota","year":"2007","journal-title":"J. Mol. Cell. Cardiol."},{"key":"2021113010411368700_B67","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1161\/ATVBAHA.110.210500","article-title":"Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway","volume":"30","author":"Ota","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010411368700_B68","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.mad.2009.06.004","article-title":"Anti-oxidative and anti-inflammatory vasoprotective effects of caloric restriction in aging: role of circulating factors and SIRT1","volume":"130","author":"Csiszar","year":"2009","journal-title":"Mech. Ageing Dev."},{"key":"2021113010411368700_B69","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.arcmed.2011.07.005","article-title":"Roles of SIRT1\u00a0in high glucose-induced endothelial impairment: association with diabetic atherosclerosis","volume":"42","author":"Yang","year":"2011","journal-title":"Arch. Med. Res."},{"key":"2021113010411368700_B70","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1042\/CS20110563","article-title":"MicroRNA-34a regulates the longevity-associated protein SIRT1\u00a0in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression","volume":"123","author":"Tabuchi","year":"2012","journal-title":"Clin. Sci."},{"key":"2021113010411368700_B71","doi-asserted-by":"publisher","first-page":"6708","DOI":"10.2741\/3183","article-title":"Role of Toll like receptor signaling pathway in ischemic coronary artery disease","volume":"13","author":"Satoh","year":"2008","journal-title":"Front. Biosci."},{"key":"2021113010411368700_B72","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1161\/ATVBAHA.106.129957","article-title":"Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells","volume":"27","author":"Kawamura","year":"2007","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010411368700_B73","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/labinvest.2009.29","article-title":"Interleukin-18 predicts atherosclerosis progression in SIV-infected and uninfected rhesus monkeys (Macaca mulatta) on a high-fat\/high-cholesterol diet","volume":"89","author":"Yearley","year":"2009","journal-title":"Lab. Invest."},{"key":"2021113010411368700_B74","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1161\/01.ATV.16.8.1000","article-title":"Interleukin-1 beta in coronary arteries of patients with ischemic heart disease","volume":"16","author":"Galea","year":"1996","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010411368700_B75","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1161\/01.CIR.0000020546.30940.92","article-title":"Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina","volume":"106","author":"Blankenberg","year":"2002","journal-title":"Circulation"},{"key":"2021113010411368700_B76","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010411368700_B77","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S0008-6363(03)00343-2","article-title":"Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice","volume":"59","author":"Elhage","year":"2003","journal-title":"Cardiovasc. Res."},{"key":"2021113010411368700_B78","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1111\/j.1600-065X.2011.01043.x","article-title":"Sensing damage by the NLRP3 inflammasome","volume":"243","author":"Leemans","year":"2011","journal-title":"Immunol. Rev."},{"key":"2021113010411368700_B79","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.1184003","article-title":"The NLRP3 inflammasome: a sensor for metabolic danger?","volume":"327","author":"Schroder","year":"2010","journal-title":"Science"},{"key":"2021113010411368700_B80","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nri2725","article-title":"NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production?","volume":"10","author":"Tschopp","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"2021113010411368700_B81","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasones","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"2021113010411368700_B82","doi-asserted-by":"publisher","first-page":"e11765","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PLoS One"},{"key":"2021113010411368700_B83","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1042\/CS20130043","article-title":"NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin","volume":"126","author":"Satoh","year":"2014","journal-title":"Clin. Sci."},{"key":"2021113010411368700_B84","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"2021113010411368700_B85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.molcel.2005.05.026","article-title":"Small RNAs: classification, biogenesis, and function","volume":"19","author":"Kim","year":"2005","journal-title":"Mol. Cells"},{"key":"2021113010411368700_B86","doi-asserted-by":"publisher","first-page":"18081","DOI":"10.1073\/pnas.0506216102","article-title":"MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation","volume":"102","author":"Felli","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010411368700_B87","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.4161\/cc.5.21.3422","article-title":"miRNAs regulate miRNAs: coordinated transcriptional and post-transcriptional regulation","volume":"5","author":"Tuccoli","year":"2006","journal-title":"Cell Cycle"},{"key":"2021113010411368700_B88","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1161\/01.RES.0000265065.26744.17","article-title":"Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells","volume":"100","author":"Suarez","year":"2007","journal-title":"Circ. Res."},{"key":"2021113010411368700_B89","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1182\/blood-2006-01-012369","article-title":"MicroRNAs modulate the angiogenic properties of HUVECs","volume":"108","author":"Poliseno","year":"2006","journal-title":"Blood"},{"key":"2021113010411368700_B90","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","article-title":"Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets","volume":"120","author":"Lewis","year":"2005","journal-title":"Cell"},{"key":"2021113010411368700_B91","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1073\/pnas.0307323101","article-title":"Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers","volume":"101","author":"Calin","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010411368700_B92","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/nar\/gki567","article-title":"Clustering and conservation patterns of human microRNAs","volume":"33","author":"Altuvia","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"2021113010411368700_B93","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2362.2009.02110.x","article-title":"Effect of atorvastatin on microRNA 221\/222 expression in endothelial progenitor cells obtained from patients with coronary artery disease","volume":"39","author":"Minami","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"2021113010411368700_B94","doi-asserted-by":"publisher","first-page":"28929","DOI":"10.1074\/jbc.M702633200","article-title":"A cellular micro-RNA, let-7i, regulates Toll-like receptor 4 expression and contributes to cholangiocyte immune responses against Cryptosporidium parvum infection","volume":"282","author":"Chen","year":"2007","journal-title":"J. Biol. Chem."},{"key":"2021113010411368700_B95","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1074\/jbc.M109.041640","article-title":"NFkappaB p50-CCAAT\/enhancer-binding protein beta (C\/EBPbeta)-mediated transcriptional repression of microRNA let-7i following microbial infection","volume":"285","author":"O'Hara","year":"2010","journal-title":"J. Biol. Chem."},{"key":"2021113010411368700_B96","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.imbio.2011.08.005","article-title":"Expression of let-7i is associated with Toll-like receptor 4 signal in coronary artery disease: effect of statins on let-7i and Toll-like receptor 4 signal","volume":"217","author":"Satoh","year":"2012","journal-title":"Immunobiology"},{"key":"2021113010411368700_B97","doi-asserted-by":"publisher","first-page":"9337","DOI":"10.1074\/jbc.M513000200","article-title":"Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism","volume":"281","author":"Mason","year":"2006","journal-title":"J. Biol. Chem."},{"key":"2021113010411368700_B98","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1161\/hq0202.104081","article-title":"Cellular antioxidant effects of atorvastatin in\u00a0vitro and in\u00a0vivo","volume":"22","author":"Wassmann","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"2021113010411368700_B99","doi-asserted-by":"publisher","first-page":"13421","DOI":"10.1073\/pnas.0801613105","article-title":"miR-34a repression of SIRT1 regulates apoptosis","volume":"105","author":"Yamakuchi","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2021113010411368700_B100","doi-asserted-by":"publisher","first-page":"712","DOI":"10.4161\/cc.8.5.7753","article-title":"MiR-34, SIRT1 and p53: the feedback loop","volume":"8","author":"Yamakuchi","year":"2009","journal-title":"Cell Cycle"}],"container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/129\/2\/93\/444050\/cs1290093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/129\/2\/93\/444050\/cs1290093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T11:31:07Z","timestamp":1638271867000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/129\/2\/93\/71335\/Cellular-and-molecular-mechanisms-of-statins-an"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,24]]},"references-count":100,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,7,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs20150027","relation":{},"ISSN":["0143-5221","1470-8736"],"issn-type":[{"value":"0143-5221","type":"print"},{"value":"1470-8736","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,24]]}}}